Pharmafile Logo

payer survey

- PMLiVE

CHMP rejects Kyowa Kirin’s Parkinson’s disease drug

Results of eight main studies of drug were 'inconsistent', according to the CHMP

- PMLiVE

Google’s DeepMind opens ‘breakthrough’ protein database to the world

AI company has mapped the structure of 98.5% of the proteins in the human body

- PMLiVE

Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader

ARV-471 is currently in a phase 2 trial for the treatment of patients ER-positive, HER2-negative locally advanced or metastatic breast cancer

- PMLiVE

Roche engaged in talks with FDA for Alzheimer’s drug candidate

CEO Severin Schwan told reporters Roche will complete a phase 3 trial of gantenerumab in the second half of 2022

- PMLiVE

One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants

New real-world data from Canada shows vaccine efficacy was lower against milder symptomatic disease with one dose

Investigating the Complexities of the Canadian & Global Health Systems

The Honourable Tony Clement, Co-chair at Reshoring Canada and former Minister of Health, discusses digital transformation, the importance of onshore manufacturing and supply chain operations in Canada, current pharmaceutical regulatory...

Impetus Digital

Impetus Digital Overview

Virtual engagement experts helping life science companies have ongoing conversations with their customers through our best-in-class online collaboration tools. Best-In-Class Collaboration Technology Impetus Digital provides two turn-key software solutions through...

Impetus Digital

Using Technology-Enabled Human Interactions to Transform the Home into a Site of Care

Sara Aghvami, Director of Best Buy Health at Best Buy Canada, explores the concept of “helpful homes” and the role of digital health in enabling “aging in place.” She also...

Impetus Digital

- PMLiVE

Langland promotes Jake Davis to managing partner

Davis joined Langland in 2020 as business unit director of the agency’s PR and policy division

- PMLiVE

Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer

Keytruda plus Lenvima was previously approved under the FDA’s accelerated approval process

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links